These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 2841731)
1. ADCC and complement-dependent lysis as immune mechanisms against EHV-1 infection in the horse. Stokes A; Wardley RC Res Vet Sci; 1988 May; 44(3):295-302. PubMed ID: 2841731 [TBL] [Abstract][Full Text] [Related]
2. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus. Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488 [TBL] [Abstract][Full Text] [Related]
3. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215 [TBL] [Abstract][Full Text] [Related]
4. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals. Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474 [TBL] [Abstract][Full Text] [Related]
5. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075 [TBL] [Abstract][Full Text] [Related]
6. The equine immune response to equine herpesvirus-1: the virus and its vaccines. Kydd JH; Townsend HG; Hannant D Vet Immunol Immunopathol; 2006 May; 111(1-2):15-30. PubMed ID: 16476492 [TBL] [Abstract][Full Text] [Related]
7. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus). Fitzpatrick DR; Studdert MJ Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). Heldens JG; Pouwels HG; van Loon AA Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389 [TBL] [Abstract][Full Text] [Related]
10. One way protection between equid herpesvirus 1 and 4 in vivo. Edington N; Bridges CG Res Vet Sci; 1990 Mar; 48(2):235-9. PubMed ID: 2159176 [TBL] [Abstract][Full Text] [Related]
11. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse. Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Goodman LB; Wagner B; Flaminio MJ; Sussman KH; Metzger SM; Holland R; Osterrieder N Vaccine; 2006 Apr; 24(17):3636-45. PubMed ID: 16513225 [TBL] [Abstract][Full Text] [Related]
14. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)--epidemiology, disease and immunoprophylaxis: a brief review. Patel JR; Heldens J Vet J; 2005 Jul; 170(1):14-23. PubMed ID: 15993786 [TBL] [Abstract][Full Text] [Related]
15. Absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells: a strategy to avoid complement-mediated lysis. van der Meulen KM; Nauwynck HJ; Pensaert MB J Gen Virol; 2003 Jan; 84(Pt 1):93-97. PubMed ID: 12533704 [TBL] [Abstract][Full Text] [Related]
16. Cellular and antibody responses to equine herpesviruses 1 and 4. Studdert MJ J Am Vet Med Assoc; 1995 Sep; 207(6):698-701. PubMed ID: 7657564 [No Abstract] [Full Text] [Related]
17. In vitro cytotoxicity of serum and peripheral blood leukocytes for equine herpesvirus type 1-infected target cells. Wilks CR Am J Vet Res; 1977 Jan; 38(1):117-21. PubMed ID: 189645 [TBL] [Abstract][Full Text] [Related]
18. [Year-round antibody profile of groups of horses of a herd kept in isolation after differently terminating use of an experimental viral combination vaccine]. Bürki F; Nowotny N; Hofer A Dtsch Tierarztl Wochenschr; 1991 Mar; 98(3):82-9. PubMed ID: 1646100 [TBL] [Abstract][Full Text] [Related]
19. Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice. Alber DG; Greensill J; Killington RA; Stokes A Res Vet Sci; 1995 Nov; 59(3):205-13. PubMed ID: 8588092 [TBL] [Abstract][Full Text] [Related]
20. Application of a type-specific enzyme-linked immunosorbent assay for equine herpesvirus types 1 and 4 (EHV-1 and -4) to horse populations inoculated with inactivated EHV-1 vaccine. Yasunaga S; Maeda K; Matsumura T; Kondo T; Kai K J Vet Med Sci; 2000 Jul; 62(7):687-91. PubMed ID: 10945284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]